Bispecific Antibodies: a Global Overview of Development as Innovative Therapeutics
J. M. Reichert

1 Reichert Biotechnology Consulting LLC
Bispecific antibodies as a class hold substantial potential as innovative therapeutic agents and bispecifics derived from a variety of platforms are beginning to enter clinical studies. An overview of the industry’s current bispecific antibody pipeline will be presented, with details of the format, targets and potential indications. The growth of the development of the bispecifics will be discussed in the context of the overall commercial pipeline of antibody therapeutics and other ‘hot’ molecules such as the antibody-drug conjugates.